<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092686</url>
  </required_header>
  <id_info>
    <org_study_id>361-302</org_study_id>
    <secondary_id>2019-000697-37</secondary_id>
    <nct_id>NCT04092686</nct_id>
  </id_info>
  <brief_title>A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to study the efficacy and safety of an investigational drug in acutely
      psychotic people with schizophrenia. Participants in the study will either receive the drug
      being studied or a placebo. This study is accepting male and female participants between 18
      -65 years old who have been diagnosed with schizophrenia. This study will be conducted in 40
      locations world wide. The study will last up to nine (9) weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating
      the efficacy and safety of two doses of SEP-363856 (75 and 100 mg/day) versus placebo over a
      6-week Treatment Period in acutely psychotic subjects with schizophrenia. This study is
      projected to randomize approximately 462 subjects to 3 treatment groups (SEP-363856 75
      mg/day, SEP-363856 100 mg/day, or placebo) in a 1:1:1 ratio. Treatment assignment will be
      stratified by country. Study drug will be taken once a day and may be taken with or without
      food.

      This study is designed to test the hypotheses that treatment with SEP-363856 in adult
      subjects with schizophrenia will result in significantly greater reduction (i.e. improvement)
      in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The
      overall Type I error is controlled for two hierarchical families of hypotheses. The first
      family includes hypotheses about the testing of change from Baseline in PANSS total score at
      Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of
      hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between
      each of the SEP-363856 dose levels vs. placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">October 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Endpoint (Week 6)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Endpoint (Week 6)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP-363856 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP-363856 75mg dosed once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEP-363856 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP-363856 100mg dosed once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dosed once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856 75mg</intervention_name>
    <description>SEP-363856 75mg tablet dosed once daily</description>
    <arm_group_label>SEP-363856 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856 100mg</intervention_name>
    <description>SEP-363856 100mg tablet dosed once daily</description>
    <arm_group_label>SEP-363856 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet dosed once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject between 18 to 65 years of age (inclusive) at the time of
             consent.

          2. Subject must give written informed consent and privacy authorization prior to
             participation in the study; adolescents must also provide informed assent.

          3. Subject meets DSM-5 criteria for schizophrenia as established by clinical interview

          4. Subject must have a CGI-S score ≥ 4

          5. Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of
             the following PANSS items: delusions, conceptual disorganization, hallucinations, and
             unusual thought content

          6. Subject has an acute exacerbation of psychotic symptoms (persisting no longer than 2
             months prior to providing informed consent).

          7. Subject has marked deterioration of functioning in one or more areas.

          8. Subject is, in the opinion of the Investigator, generally healthy based on screening
             medical history, PE, neurological examination, vital signs, and clinical laboratory
             values.

        Exclusion Criteria:

          1. Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5
             diagnosis other than schizophrenia. Exclusionary disorders include but are not limited
             to alcohol use disorder (within past 12 months), substance (other than nicotine or
             caffeine) use disorder within past 12 months, major depressive disorder, bipolar I or
             II disorder, schizoaffective disorder, obsessive compulsive disorder, and
             posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety
             are allowed so long as these symptoms are not the primary focus of treatment.

          2. Subject is at significant risk of harming self, others, or objects based on
             Investigator's judgment.

          3. Subject has any clinically significant unstable medical condition or any clinically
             significant chronic disease that in the opinion of the Investigator, would limit the
             subject's ability to complete and/or participate in the study

          4. Female subject who is pregnant or lactating

          5. Subject has any clinically significant abnormal laboratory value(s) at Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CNS Medical Director</last_name>
    <phone>1-866-503-6351</phone>
    <email>ClinicalTrialDisclosure@sunovion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Billingsley, MD</last_name>
      <phone>479-927-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling, MD</last_name>
      <phone>714-799-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Neuropsychopharmacology Clinical Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Benbow, MD</last_name>
      <phone>619-481-5252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center UCSD Department of Psychiatry</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mounir Soliman, MD</last_name>
      <phone>619-543-6446</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schuster Medical Research Institute</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Itzcovich-Schuster, MD</last_name>
      <phone>818-788-0746</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kashinath Yadalam, MD</last_name>
      <phone>337-564-6405</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Hassman, MD</last_name>
      <phone>856-452-9901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Lieberman, MD</last_name>
      <phone>646-774-5300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Bartley, MD</last_name>
      <phone>214-396-4844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Centre, Prof. Dr. Ivan Temkov, Burgas EOOD, Department for Treatment of Emergency Psychiatric Conditions</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Temkov, MD</last_name>
      <phone>+359888451225</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Psychiatric Hospital - Kardzhali, First Woman Department, Third Men Deparment</name>
      <address>
        <city>Kardzhali</city>
        <zip>6600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rozaliya Rangelova, MD</last_name>
      <phone>+359889903682</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Psychiatric Hospital Sv. Ivan rilski-Department General Psychiatry for Adults &quot;closed&quot; Type -Men, Department General Psychiatry for Adults, &quot;Closed&quot; Type - Women</name>
      <address>
        <city>Novi Iskar</city>
        <zip>1282</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsvetesiava Galabova, MD</last_name>
      <phone>+3599917215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveti Georgi EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Popov, MD</last_name>
      <phone>+359888498975</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD Psychoeurological Hospital of Daugavpils</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Sapele</last_name>
      <phone>+37165402223</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SLLC Riga Centre of Psychiatry and Narcology</name>
      <address>
        <city>Riga</city>
        <zip>LV-1005</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elmars Rancans, Professor</last_name>
      <phone>+37167080131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SLLC Psychoneurological Hospital of Strenci</name>
      <address>
        <city>Strenci</city>
        <zip>LV-4730</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inga Bauska, MD</last_name>
      <phone>+37164731340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Public Institution of Healthcare Leningrad Regional Psychoneurological Dispensary</name>
      <address>
        <city>Leningrad</city>
        <zip>188820</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Penchul, MD</last_name>
      <phone>+78137864178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Moscow &quot;Psychiatric Clinical Hospital #1 named after N.A. Alekseev of Department of Healthcare of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>117152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anatoly Smulevich, MD</last_name>
      <phone>+74959528331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Moscow &quot;Psychiatric Hospital No. 5&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>141371</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Arbuzov, MD</last_name>
      <phone>+74965431346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Institution of Healthcare &quot;Psychiatric Hospital named after P.P. Kashchenko, inpatient No 2 leg add</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liudmila Shapovalova, MD</last_name>
      <phone>+79112700727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI- &quot;NMRC of Psychiatry and Neurology named after V.M. Bekhterev&quot; MoH RF3</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay Nezanov, MD</last_name>
      <phone>+78125675406</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Public Institution of Healthcare &quot;City Psychiatric Hospital #3 named after I.I. Skvortsov-Stepanov&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Sofronov, MD</last_name>
      <phone>+78123018654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Public Institution of Healthcare &quot;City Psychiatric Hospital #3 named after I.I. Skvortsov-Stepanov&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Sofronov, MD</last_name>
      <phone>+79030951679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare &quot;Saratov City Clinical Hospital #2 named after V.I. Razumovskiy&quot; 20 and 21 departments</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Barylnik, MD</last_name>
      <phone>+79272266850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare Regional Clinical Psychiatric Hospital of Saint Sofia</name>
      <address>
        <city>Saratov</city>
        <zip>410060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Ivlieva</last_name>
      <phone>+78452955048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;NMRC of Psychiatry and Neurology named after V.M. Bekterev&quot; MoH RF</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Ivanov, MD</last_name>
      <phone>+79219306167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Psychiatry, Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Ivkovic, PhD</last_name>
      <phone>+38163252201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Special Neuropsychiatric Hospital Kovin</name>
      <address>
        <city>Kovin</city>
        <zip>26220</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Snezana Djordjevic, MD</last_name>
      <phone>+381641438246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Psychiatry, clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjana Jovanovic, Professor</last_name>
      <phone>+38134370151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Psychiatry, Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goran Mihajlovic, Professor</last_name>
      <phone>+38134300320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Special Hospital for Psychiatric Disease Sveti Vracevi</name>
      <address>
        <city>Novi Knezevac</city>
        <zip>23330</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jovan Milovanovic, MD</last_name>
      <phone>+38163239962</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>46 Academician Pavlov St</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktor Kovalenko</last_name>
      <phone>+380577381062</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine, Department of Boundary Psychiatry</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Maruta</last_name>
      <phone>+380677577772</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communica Noncommercial Enterprise Kherson Regional Institution of Psychiatric Care Assistance of Kherson Regional Council, Male Department of Psychiatry #3, Female Department of Psychiatry #10</name>
      <address>
        <city>Kherson</city>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavlo Palamarchuk, MD</last_name>
      <phone>+38504940457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyev Clinical Hospital on Railway Station #1 of Healthcare Center branch of JSC &quot;Ukrainian railway&quot; Department of Psychoneurology</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Chaban</last_name>
      <phone>+380444651721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Military and Medical Clinical Center, The Main Military Clinical Hospital, Psychiatric Clinic with Wards for Narcological Patients</name>
      <address>
        <city>Kyiv</city>
        <zip>01133</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ievgeniia Grynevych</last_name>
      <phone>+380996423313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Institution of Kyiv Regional Council Regional Psychiatric and Narcological Medical Association, Male Department #10, Female Department #2</name>
      <address>
        <city>Kyiv</city>
        <zip>08631</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gennadii Ziberblat</last_name>
      <phone>+380506480750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Enterprise of Lviv Regional Concil Lviv Regional Clinical Psychiatric Hospital, Department #20</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateryna Zakal</last_name>
      <phone>+380677672919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Institution O.I. Yuschenko Vinnytsia Regional Psychoneurological Hospital, Male Department #21, Female Department #15, M.I. Pyrogov Vinnytsia National Medical University, Chair of Psychiatry, Narcology and Psychotherapy with Postgraduate Educatio</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana Serebrennnikova, MD</last_name>
      <phone>+380679605672</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute psychosis</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study may be made available upon request via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available upon request within 12 months of posting the study results on ct.gov.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

